In this meta-analysis of 23 randomized CHF trials (>95% of patients had systolic dysfunction), pooled analysis showed beta blockers conferred a significant mortality benefit (risk ratio 0.76, CI 0.68-0.84). They did not find an association between mortality and beta blocker dose, but did find a linear association between mortality and heart rate (with an 18% relative risk reduction for every 5 fewer beats per minute). Beta blockers should be titrated by heart rate, not dose, to achieve mortality benefits in patients with systolic CHF (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]